跳至主要内容
临床试验/NCT00772512
NCT00772512已完成1 期

Subject- And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 3-Way Crossover Study To Study Effects Of PF-04802540 On Polysomnography Endpoints In Healthy Volunteers

Taisho Pharmaceutical Co., Ltd.1 个研究点 分布在 1 个国家目标入组 13 人开始时间: 2008年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
13
试验地点
1
主要终点
REM sleep percentage

研究概览

简要总结

The purpose of this study is to determine if PF-04802540 decreases REM sleep.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and/or female (nonchildbearing potential) subjects between the ages of 18 and 55 years, inclusive
  • Body Mass Index (BMI) between 18 to 32 kg/m2, inclusive, and a total body weight >45 kg (99 lbs)
  • Non-users of nicotine

排除标准

  • Evidence or history of clinically significant medical illness
  • A history of seizures, including childhood febrile seizures
  • Any condition possibly affecting drug absorption

研究组 & 干预措施

A

Experimental

干预措施: PF-04802540 (Drug)

B

Experimental

干预措施: PF-04802540 (Drug)

C

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

REM sleep percentage

时间窗: 1 day

次要结局

  • REM sleep latency(1 day)
  • Beta EEG power(1 day)
  • Plasma concentrations of PF-04802540 and its metabolite, PF-04831035(2 days)

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验